Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | DDX3X | O00571 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5272228 | 0.84 | NPC1 (0.54) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL14561170 | 0.84 | RAB9A (0.67) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL7104543 | 0.84 | RAB9A (0.62) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL5274549 | 0.83 | SMN1; SMN2 (0.61) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL7100059 | 0.82 | RAB9A (0.61) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL5683215 | 0.82 | DDX3X (0.65) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL3485567 | 0.81 | ITGB1 (0.67) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL8231040 | 0.81 | ITGB1 (0.61) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL14500971 | 0.81 | RAB9A (0.59) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL29612679 | 0.81 | ITGB1 (0.67) | RAB9ANPC1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6191171-B1 | ANTAGONISTS, USEFUL IN INHIBITION OR PREVENTION OF CELL ADHESION AND CELL-ADHESION MEDIATED PATHOLOGIES; FOR DRUGS FOR TREATMENT OF ASTHMA, ALLERGIES, INFLAMMATION, MULTIPLE SCLEROSIS, AND OTHER INFLAMMATORY AND AUTOIMMUNE DISORDERS | MERCK & CO., INC. | 2001-02-20 | — | — | US | claimed |
| WO-1999026923-A1 | PARA-AMINOMETHYLARYL CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-0842196-B1 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-1091943-B1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PROD INC (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2001051487-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6248713-B1 | OLIGOPEPTIDE FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BIOGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| EP-1091943-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | Pfizer Products Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| US-6191171-B1 | ANTAGONISTS, USEFUL IN INHIBITION OR PREVENTION OF CELL ADHESION AND CELL-ADHESION MEDIATED PATHOLOGIES; FOR DRUGS FOR TREATMENT OF ASTHMA, ALLERGIES, INFLAMMATION, MULTIPLE SCLEROSIS, AND OTHER INFLAMMATORY AND AUTOIMMUNE DISORDERS | MERCK & CO., INC. | 2001-02-20 | — | — | US | disclosed |
| US-6020347-A | 4-substituted-4-piperidine carboxamide derivatives | MERCK & CO., INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-2000000477-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999026923-A1 | PARA-AMINOMETHYLARYL CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999025685-A1 | 4-SUBSTITUTED-4-PIPERIDINE CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0842196-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | RAB9A 1592/4885NPC1 3565/4885MAPT 4088/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | RAB9A 2130/4885NPC1 2481/4885MAPT 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.